Author Interviews, BMJ, Karolinski Institute, Rheumatology / 06.06.2014
Rheumatoid Arthritis: Personalized Treatment Approach Guided By MBDA Score
MedicalResearch.com Interview with:
Karen Hambardzumyan
Research Assistant
Karolinska Institute
Department of Medicine, (ClinTRID)
D1:00, Karolinska University Hospital
Solna Stockholm
MedicalResearch: What are the main findings of the study?
Answer: One of the difficulties with rheumatoid arthritis (RA) treatment is unpredictable treatment outcome at the individual patient level. The course might be mild or severe independently of the therapy. To identify subgroups of patients who will benefit from specific therapy strategies is one of the goals for today’s rheumatologists. We have investigated a Multi-Biomarker Disease Activity (MBDA) score in patients from the Swedish Farmacotherapy (SWEFOT) clinical trial, where early rheumatoid arthritis patients were included/studied. The main finding was the usefulness of the MBDA score for prediction of those patients who will not get joint damage detected by X-rays (radiographic progression) during one year follow-up. This MBDA score, developed by Crescendo Bioscience (South San-Francisco, CA, USA) is based on serum levels of 12 different protein biomarkers and can categorize patients into 3 groups: patients with low, moderate and high disease activity. Ninety-seven percent of patients who had low or moderate MBDA score before treatment onset, did not experience radiographic progression during one year follow-up. This finding could contribute to a personalised approach to the RA patients for the optimal therapy choice.
(more…)